Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cellss

Molecular Pharmacology

Volumn 84, Issue 1, 2013, Pages 25-40

  Dovizio, Melania ^a   Maier, Thorsten J ^b   Alberti, Sara ^a   Francesco, Luigia Di ^a   Marcantoni, Emanuela ^a   Munch, Gotz ^c   John, Constance M ^d   Suess, Beatrix ^e   Sgambato, Alessandro ^f   Steinhilber, Dieter ^b   Patrignani, Paola ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b GOETHE UNIVERSITY   (Germany)

^c CorImmun GmbH ^*  (Germany)

^d MandalMed Inc   (United States)

^e DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

^f CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN RECEPTOR; CYCLOOXYGENASE 2; GALECTIN 3; MESSENGER RNA; PADGEM PROTEIN; PROSTAGLANDIN E2; REVACEPT; ROFECOXIB; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CONTACT; CELL INTERACTION; COLON CARCINOMA; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; UPREGULATION;

BINDING SITES; BLOOD PLATELETS; CELL COMMUNICATION; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYCLIN B1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; GALECTIN 3; GENE EXPRESSION; GLYCOPROTEINS; HT29 CELLS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; LACTONES; LACTOSE; PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, COLLAGEN; RNA, MESSENGER; SULFONES; UP-REGULATION;

EID: 84879088346     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.084988     Document Type: Article

References (52)

1. Algra AM and Rothwell PM (2012) Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 13:518-527.
2. Appeldoorn CC, Molenaar TJ, Bonnefoy A, van Leeuwen SH, Vandervoort PA, Hoylaerts MF, van Berkel TJ, and Biessen EA (2003) Rational optimization of a short human P-selectin-binding peptide leads to nanomolar affinity antagonists. J Biol Chem 278:10201-10207.
3. Bender M, Hofmann S, Stegner D, Chalaris A, Bösl M, Braun A, Scheller J, Rose-John S, and Nieswandt B (2010) Differentially regulated GPVI ectodomain shedding by multiple platelet-expressed proteinases. Blood 116:3347-3355.
4. Bhattacharya M, Peri KG, Almazan G, Ribeiro-da-Silva A, Shichi H, Durocher Y, Abramovitz M, Hou X, Varma DR, and Chemtob S (1998) Nuclear localization of prostaglandin E2 receptors. Proc Natl Acad Sci USA 95:15792-15797.
5. Bhattacharya M, Peri K, Ribeiro-da-Silva A, Almazan G, Shichi H, Hou X, Varma DR, and Chemtob S (1999) Localization of functional prostaglandin E2 receptors EP3 and EP4 in the nuclear envelope. J Biol Chem 274:15719-15724.
6. Boukerche H, Berthier-Vergnes O, Tabone E, Doré JF, Leung LL, and McGregor JL (1989) Platelet-melanoma cell interaction is mediated by the glycoprotein IIb-IIIa complex. Blood 74:658-663.
7. Buchdunger E, O'Reilly T, and Wood J (2002) Pharmacology of imatinib (STI571). Eur J Cancer 38 (Suppl 5):S28-S36.
8. Cha YI and DuBois RN (2007) NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 58:239-252.
9. Chari R, Getz T, Nagy B, Jr., Bhavaraju K, Mao Y, Bynagari YS, Murugappan S, Nakayama K, and Kunapuli SP (2009) Protein kinase C[delta] differentially regulates platelet functional responses. Arterioscler Thromb Vasc Biol 29:699-705.
10. Coppinger JA, O'Connor R, Wynne K, Flanagan M, Sullivan M, Maguire PB, Fitzgerald DJ, and Cagney G (2007) Moderation of the platelet releasate response by aspirin. Blood 109:4786-4792.
11. Dixon DA, Tolley ND, Bemis-Standoli K, Martinez ML, Weyrich AS, Morrow JD, Prescott SM, and Zimmerman GA (2006) Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling. J Clin Invest 116:2727-2738
12. Doller A, Winkler C, Azrilian I, Schulz S, Hartmann S, Pfeilschifter J, and Eberhardt W (2011) High-constitutive HuR phosphorylation at Ser 318 by PKCdelta propagates tumor relevant functions in colon carcinoma cells. Carcinogenesis 32:676-685.
13. Dovizio M, Bruno A, Tacconelli S, and Patrignani P (2013) Mode of action of aspirin as a chemopreventive agent. Recent Results Cancer Res 191:39-65.
14. Dovizio M, Tacconelli S, Ricciotti E, Bruno A, Maier TJ, Anzellotti P, Di Francesco L, Sala P, Signoroni S, and Bertario L et al. (2012) Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. J Pharmacol Exp Ther 341:242-250.
15. Fukushi J, Makagiansar IT, and Stallcup WB (2004) NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin. Mol Biol Cell 15:3580-3590.
16. Gardiner EE, Arthur JF, Kahn ML, Berndt MC, and Andrews RK (2004) Regulation of platelet membrane levels of glycoprotein VI by a platelet-derived metalloproteinase. Blood 104:3611-3617.
17. Gay LJ and Felding-Habermann B (2011) Contribution of platelets to tumour metastasis. Nat Rev Cancer 11:123-134.
18. Gillis LD, Leidal AM, Hill R, and Lee PW (2009) p21Cip1/WAF1 mediates cyclin B1 degradation in response to DNA damage. Cell Cycle 8:253-256.
19. Halder SK, Beauchamp RD, and Datta PK (2005) A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia 7:509-521.
20. Hamberg M, Svensson J, and Samuelsson B (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72:2994-2998
21. Heldin CH and Westermark B (1999) Mechanism of action and in vivo role of plateletderived growth factor. Physiol Rev 79:1283-1316.
22. Hourani SM, Hall DA, and Nieman CJ (1992) Effects of the P2-purinoceptor antagonist, suramin, on human platelet aggregation induced by adenosine 59-diphosphate. Br J Pharmacol 105:453-457.
23. John CM, Leffler H, Kahl-Knutsson B, Svensson I, and Jarvis GA (2003) Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. Clin Cancer Res 9:2374-2383.
24. Kalluri R and Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119:1420-1428
25. Konger RL, Billings SD, Thompson AB, Morimiya A, Ladenson JH, Landt Y, Pentland AP, and Badve S (2005) Immunolocalization of low-Affinity prostaglandin E receptors, EP and EP, in adult human epidermis. J Invest Dermatol 124:965-970.
26. Labelle M, Begum S, and Hynes RO (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20:576-590.
27. Li CY, Suardet L, and Little JB (1995) Potential role of WAF1/Cip1/p21 as a mediator of TGF-beta cytoinhibitory effect. J Biol Chem 270:4971-4974.
28. Mannori G, Crottet P, Cecconi O, Hanasaki K, Aruffo A, Nelson RM, Varki A, and Bevilacqua MP (1995) Differential colon cancer cell adhesion to E-, P-, and Lselectin: role of mucin-type glycoproteins. Cancer Res 55:4425-4431.
29. Markowska AI, Liu FT, and Panjwani N (2010) Galectin-3 is an important mediator of VEGF-And bFGF-mediated angiogenic response. J Exp Med 207: 1981-1993.
30. Matsui Y, Amano H, Ito Y, Eshima K, Suzuki T, Ogawa F, Iyoda A, Satoh Y, Kato S, and NakamuraM et al. (2012) Thromboxane A receptor signaling facilitates tumor colonization through P-selectin-mediated interaction of tumor cells with platelets and endothelial cells. Cancer Sci 103:700-707.
31. Mirandola L, Yu Y, Chui K, Jenkins MR, Cobos E, John CM, and Chiriva-Internati M (2011) Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma. PLoS ONE 6: e21811.
32. Morita I, Schindler M, Regier MK, Otto JC, Hori T, DeWitt DL, and Smith WL (1995) Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem 270:10902-10908
33. Nangia-Makker P, Balan V, and Raz A (2008) Regulation of tumor progression by extracellular galectin-3. Cancer Microenviron 1:43-51.
34. Nieswandt B and Watson SP (2003) Platelet-collagen interaction: is GPVI the central receptor? Blood 102:449-461.
35. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, Cipollone F, Ganci A, Créminon C, and Maclouf J et al. (1994) Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 271:1705-1712.
36. Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, and Peskar BA (1980) Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 17:317-327.
37. Patrono C, García Rodríguez LA, Landolfi R, and Baigent C (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373-2383.
38. Patrono C, Patrignani P, and García Rodríguez LA (2001) Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 108:7-13.
39. Prescott SM (2000) Is cyclooxygenase-2 the alpha and the omega in cancer? J Clin Invest 105:1511-1513.
40. Regan JW (2003) EP2 and EP4 prostanoid receptor signaling. Life Sci 74:143-153.
41. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M, and Mehta Z et al. (2012b) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379:1602-1612.
42. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, and Mehta Z (2012a) Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379:1591-1601.
43. Satelli A, Rao PS, Gupta PK, Lockman PR, Srivenugopal KS, and Rao US (2008) Varied expression and localization of multiple galectins in different cancer cell lines. Oncol Rep 19:587-594.
44. Schlötzer-Schrehardt U, Zenkel M, and Nüsing RM (2002) Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci 43:1475-1487.
45. Tong DD, Jiang Y, Li M, Kong D, Meng XN, Zhao YZ, Jin Y, Bai J, Fu SB, and Geng JS (2009) RUNX3 inhibits cell proliferation and induces apoptosis by TGF-betadependent and -independent mechanisms in human colon carcinoma cells. Pathobiology 76:163-169.
46. Ungerer M, Rosport K, Bültmann A, Piechatzek R, Uhland K, Schlieper P, Gawaz M, and Münch G (2011) Novel antiplatelet drug revacept (dimeric glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation 123:1891-1899.
47. Wang Y, Balan V, Kho D, Hogan V, Nangia-Makker P, and Raz A (2012) Galectin-3 regulates p21stability in human prostate cancer cells. Oncogene DOI: [published ahead of print].
48. Wang Y, Ji P, Liu J, Broaddus RR, Xue F, and Zhang W (2009) Centrosomeassociated regulators of the G(2)/M checkpoint as targets for cancer therapy. Mol Cancer 8:8
49. Winesett MP, Ramsey GW, and Barnard JA (1996) Type II TGF(beta) receptor expression in intestinal cell lines and in the intestinal tract. Carcinogenesis 17: 989-995.
50. Yang L, Lin C, and Liu ZR (2006) P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from beta-catenin. Cell 127: 139-155.
51. Yang RY, Rabinovich GA, and Liu FT (2008) Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 10:e17.
52. Young LE, Sanduja S, Bemis-Standoli K, Pena EA, Price RL, and Dixon DA (2009) The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis. Gastroenterology 136:1669-1679. Della Ricerca Biomedicine